STRAVINSKY- Stratification of Clinically Vulnerable People for COVID19
Research type
Research Study
Full title
STRAVINSKY- Stratification of Clinically Vulnerable People for COVID-19
IRAS ID
325967
Contact name
Alex Richter
Contact email
Sponsor organisation
University of Birmingham , Head of Research Governance & Integrity
Duration of Study in the UK
2 years, 11 months, 15 days
Research summary
Although the COVID-19 vaccination program has proved extraordinarily successful, clinically vulnerable (CV) patients remain at risk of SARS-CoV-2 infection, severe COVID-19 and death. Large (inter)national studies, have previously identified some patient groups who make sub-optimal immune responses to COVID-19 vaccines, and those at highest risk of severe COVID-19. Although the precise immune correlates of protection against severe COVID-19 are not defined, recent emerging data in patient groups suggests that the serological response to vaccination is a critical determinant in COVID-19 outcomes. Disease cohorts may be particularly informative in defining correlates of protection, as vaccine immune responses are heterogeneous such that correlations of these with disease outcomes is possible. In this study we will i) assess if SARS-CoV-2 serological responses to COVID19 vaccines can be used to risk stratify CV people for COVID19 clinical outcomes and ii) perform a retrospective meta-analysis using previous studies to enhance stratification of patient groups for clinical risk.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
23/EE/0129
Date of REC Opinion
14 Jun 2023
REC opinion
Favourable Opinion